FDA Muscles Darvocet and Darvon Off the Market
Written By: Rheingold, Giuffra, Ruffo & Plotkin LLP
More than a year after the European Medicines Agency recommended the pain killing drug propoxyphene, marketed as Darvocet and Darvon, be taken off the market, the Food and Drug Administration has convinced the makers of the name brand drug to do the same.
New research shows that the popular pain killer causes an increased chance of heart problems, such as cardiac arrhythmias. In adding this increased risk, coupled with it's minimal effects in reducing pain, the FDA decided that the benefits no longer outweighed the risks in prescribing this drug.
Gerald Dal Pan, the director of the FDA's Office of Surviellance and Epidemiology, released a statement saying, "With the new study results, dor the first time we now have data showing that the standard therapeutic dose of propoxyphene can be harmful to the heart. This new heart data significantly alter propoxyphene's risk-benefit profile."
If you have taken Darvocet or Darvon and have been diagnosed with cardiac arrhythmias, contact a lawyer at Rheingold, Giuffra, Ruffo & Plotkin LLP for a free consultation.